Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07303803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

Study acronym: CHIG-MASH
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment openedv3 Show 4 more changesShow less
    • Eligibility criteria shortened, about 22 words
    • Secondary endpoints: 9 to 10
    • Study description revised
    • Site details revised at 17 of 17 sites
  2. Eligibility criteria revised
    • Study sites revised (17)
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial aims to evaluate the efficacy and safety of chiglitazar as a combination therapy for patients with MASH and T2DM.
Trial Details
NCT Number NCT07303803
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Collaborators: Chipscreen Biosciences, Ltd.
Conditions
(from sponsor)		 MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus)
Related terms Diabetes Mellitus, Type 2
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov